Skip to main navigation
Harrow Health

> Main Menu

About Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency
Careers
Contact
Investors Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

> Main Menu

About
Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency
Careers Contact
Investors
Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

Press Releases

September 26, 2023
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
August 9, 2023
Harrow Announces Second Quarter 2023 Financial Results
July 31, 2023
Harrow Launches VIGAMOX® in the U.S.
July 26, 2023
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
July 19, 2023
Harrow Prices $60 Million Public Offering of Common Stock
July 18, 2023
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
July 18, 2023
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
July 18, 2023
Harrow Announces Proposed Public Offering of Common Stock
July 18, 2023
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
May 17, 2023
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 23
Harrow Health

Address

102 Woodmont Blvd., Suite 610
Nashville, TN 37205

Phone

(615) 733 4730
(615) 733 4737 (Investor Relations)

Social

LinkedIn

© 2023 Harrow Health, Inc.

> Footer

Privacy Policy Cookie Notice